OncoMatch/Clinical Trials/NCT04992559
A Study of Toripalimab as Consolidation Therapy After Postoperative Chemoradiotherapy in HNSCC
Is NCT04992559 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Consolidation Toripalimab for head and neck squamous cell carcinomas.
Treatment: Consolidation Toripalimab — This study is a phase II, open label, single-arm and exploratory clinical trial. The purpose of this study is to observe the efficacy and safety of consolidation immunotherapy with Toripalimab following postoperative radiotherapy or chemoradiotherapy for patients with locally advanced head and neck squamous cell carcinomas (HNSCC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage III
locally advanced head and neck squamous cell carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: radiation therapy — postoperative adjuvant
Have received postoperative adjuvant radiotherapy (chemo) therapy, and the end of the treatment is not more than 2 months.
Cannot have received: anti-PD-1 therapy
Has received prior therapy with an anti-PD-1 antibody
Cannot have received: investigational agent
Is currently participating in or has participated in a study of an investigational agent within 4 weeks of the first dose of treatment
Lab requirements
Blood counts
Absolute Neutrophil Count >1,500/µL; Platelets > 100 X 10^3/µL; Hemoglobin > 9.0 g/dL
Kidney function
Serum creatinine < 1.5 X ULN or CrCl > 40mL/min
Liver function
AST/ALT ≤ 3 x ULN; Total Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL)
Adequate hepatic and renal function as demonstrated by... Adequate bone marrow function as demonstrated by...
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04992559 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-PD-1 therapy, investigational agent disqualifies patients from enrollment.
What disease stage is eligible?
Stage III is required.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages